International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 124 | Views: 201

Research Paper | Medical Surgical | India | Volume 4 Issue 7, July 2015 | Rating: 6.7 / 10


High Grade Gliomas: Newer Horizon-New Hope

Sridhar.P [4] | Balu.S [2] | Pramod.K.P.R | Ibrahim Khaleel [2] | Govardhan H. B.


Abstract: Objective Malignant Gliomas are the most aggressive cancers producing severe and progressive disability, usually leading to death. The standard treatment consists of Cytoreductive Surgery followed by Radiotherapy and Concurrent Temozolomide and Adjuvant Temozolomide. Optimizing the adjuvant chemotherapy regime is one potential strategy for improving survival and Quality of life Methods In this study, 40 diagnosed patients of high grade gliomas, who underwent resection, received concurrent chemoradiation and adjuvant chemotherapy were analysed. [25 pts- Anaplastic Astrocytoma (Gr III), 13 pts- Glioblastoma Multiforme (GBM) & 2 pts- Gliosarcoma]. Patients received concurrent Temozolomide 75 mg/m2 daily for 42 days. Weekly Hematological and Biochemical investigations were done.4 weeks after chemo-irradiation, patients received Adjuvant Temozolomide-150 mg/m2 days 1 to7 and days 15 to 21 for every 28 days for 6 cycles. Investigations were done every 2weeks (Hematological and Biochemical parameters were assessed). Response rate, survival outcome, recurrence rates & toxicities were analyzed. The response was assessed with CT/MRI every 3 monthly from the time of completion of treatment. Results The overall survival in high grade glioma was 38.3 months. In Anaplastic astrocytoma (Gr III), maximum survival was 44 months and in Glioblastoma multiforme it was 26.6 months. The survival between the grades is significant with p value of 0.001, significant better 2year OS was seen in AA (Gr III). There were 10 deaths due to disease progression, out of which 8 cases were GBM and 2 cases were AA (Gr III).18 pts developed Gr-III Thrombocytopenia and 16 patients had Leukopenia (Gr I-II). None of the patients developed Gr-IV hematological toxicities. Nausea and vomiting (Grade 1-2) was seen in 80 % of the patients. Conclusion Dose dense regimen has a role in terms of efficacy than the adjuvant treatment of standard dose of 200 mg/m2 days 1 to 5 for every 28 days cycle for 6 months. The toxicity is increased with majority being Grade I, II leucopenia and Grade III Thrombocytopenia


Keywords: High Grade Glioma, Anaplastic astrocytoma, Glioblastoma multiforme, Temozolomide, MGMT- O6 methyl guanine DNA methyl transferase


Edition: Volume 4 Issue 7, July 2015,


Pages: 1136 - 1138


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top